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ThehumanLHreceptor (LHR)plays akey role in luteal functionand theestablishmentofpregnancy
through its interaction with the gonadotropins LH and human chorionic gonadotropin. We pre-
viously identified four splice variants of the LHR in human luteinized granulosa cells (LGCs) and
corpora lutea (CL). Real-time quantitative PCR revealed that expression of the full-length LHR
(LHRa) and the most truncated form (LHRd) changed significantly in CL harvested at different
stages of the ovarian cycle (P  0.01, ANOVA). LHRa expression was reduced in the late luteal CL
(P 0.05). Conversely, an increase in LHRd expressionwas observed in the late luteal CL (P 0.01).
Chronic manipulation of human chorionic gonadotropin in LGC primary cultures supported the in
vivo findings. LHRd encodes a protein lacking the transmembrane and carboxyl terminal domains.
COS-7 cells expressing LHRd were unable to produce cAMP in response to LH stimulation. COS-7
cells coexpressing LHRd and LHRa also failed to generate cAMP in response to LH, suggesting that
this truncated form has a negative effect on the signaling of LHRa. Immunofluorescence staining
ofLGCandCOS-7cells implied that there isa reduction incell surfaceexpressionofLHRawhenLHRd
is present. Overall, these results imply expression of LHR splice variants is regulated in the human
CL. Furthermore, during functional luteolysis a truncated variant could modulate the cell surface
expression and activity of full-length LHR. (Endocrinology 150: 2873–2881, 2009)
The LH receptor (LHR) is a member of the G protein-coupledreceptor (GPCR) superfamily and consists of an extracellu-
lar domain, seven-transmembrane domains connected by alter-
nating intracellular and extracellular loops, and an intracellular
carboxyl (C) terminal tail (1). The LHR has a pivotal role in
human corpus luteum (CL) function through its interactionwith
the gonadotropins LH and human chorionic gonadotropin
(hCG). Luteal progesterone production is dependent on LHR
stimulation. During luteolysis progesterone production initially
falls despite continued expression of LH (2), LHR (3), and fac-
tors downstream of the progesterone synthetic pathway (4).
However, during pregnancy hCG, acting through the LHR, res-
cues the CL from luteolysis and progesterone secretion is main-
tained. Although this is crucial for human reproduction, how the
CL is regulated at a molecular level is not known.
The LHR may increasingly lose its function as luteolysis is ap-
proached. Loss of LHR function occurs in patientswith Leydig cell
hypoplasiawhohavemutations in exons8and10of thegene (5,6).
Furthermore, human LHR without exon 10 is responsive to hCG
but not LH (7). This LHR isoform is the naturally produced recep-
tor in the marmoset monkey (8) in which CG is the significant
pituitary gonadotropin (9). If the LHR variant without exon 10
exists in the human ovary, this could explain how the CL is able to
respond to hCG and not LH during pregnancy.
Transcripts encoding alternatively spliced variants of the
LHR have been detected in the rat (10), pig (11), sheep (12),
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horse (13), cow (14), and human (15) CL. A transcript variant
with exon 10 spliced out was detected in the sheep (12) and cow
(16) CL, but we did not identify this transcript in the human
ovary (17). However, we did find three alternative splice vari-
ants of the LHR in human CL and luteinized granulosa cells
(LGCs). LHRa encoded the full-length receptor. LHRb was
missing exon 9, whereas LHRc and LHRd were lacking the
first 266 nucleotides of exon 11. Exon 9 was removed in
LHRd, too (17) (Fig. 1A). Exon 9 encodes part of the leucine-
rich motif and hinge regions of the extracellular domain.
LHRb was unable to bind hCG or activate second messenger
signaling indicating that exon 9 is important for these func-
tions (18, 19). The deletion of part of exon 11 causes a frame
shift in the reading frame and creates a truncated protein that
is missing amino acids 317-699 of the full-length sequence.
The insertion of a different 13-amino acid stretch of sequence
creates a unique C terminus preceding a premature stop
codon. The LHRc and LHRd proteins are therefore missing
part of the hinge region, transmembrane domains, and C-
terminal tail.
FSH and follicle size regulate alternative splicing of the cow
LHR (20). Furthermore, LHRb formed receptor complexes
with, as well as negatively regulated the expression and activity
of, LHRa and FSH receptor (FSHR) (19, 21, 22). A rat LHR
truncated variant, similar in structure to humanLHRd, also con-
trolled cell surface expression of LHRa (23).
We hypothesized that as the human CL ages, there is an in-
crease in the production of alternatively spliced LHRs that in-
hibit LH signaling. We studied the expression and regulation of
LHR splice variants in human CL across the luteal phase and in
LGCs. Additionally, we examined the functional significance of
the most abundant splice variant, LHRd.
Materials and Methods
Collection of human CL
Tissue collection was approved by the local medical research ethics
committee. With patient consent, human CL (n  13) were enucleated
at the time of surgery from women with regular menstrual cycles under-
going hysterectomy for benign conditions and dated on the basis of the
urinaryLHsurge (24). In this study, fourCLwere classifiedas early luteal
(LH1 to LH5), four as midluteal (LH6 to LH10), and five as late
luteal (LH11 to LH14).
Isolation of primary cells
The medical ethics committee separately approved the collection
of cells. With patient consent, follicular fluid was collected from
women undergoing transvaginal oocyte retrieval for in vitro fertili-
zation (25). LGCs were isolated using Percoll density gradient cen-
trifugation (26, 27).
Cell culture
All cells were maintained at 37 C, 5% CO2. Pooled LGCs (1–1.5 
105 cells/well of three to five patients) were cultured in plates precoated
with matrigel (BD Biosciences, Bedford MA) in serum-free medium (in-
sulin transferrin-sodium selenite supplemented DMEM/F12 Ham mix-
ture; Life Technologies, Inc., Gaithersburg,MD). After 6–8 d, cells were
treated with recombinant hCG (Serono Laboratories, Welwyn Garden
City, UK; 100 ng/ml) and low-density lipoprotein (LDL; Sigma-Aldrich
FIG. 1. A, Domain structure of LHR isoforms. The LHRa transcript contains all 11
exons and encodes the full-length receptor. The LHRb transcript is missing exon 9
and therefore encodes a protein lacking part of the LRR and H regions. The LHRc
and LHRd transcripts are missing the first 266 nucleotides of exon 11, which
causes a frame shift and premature stop codon. These transcripts are therefore
missing the rest of exon 11, which encodes the T and C regions. The LHRd
transcript is also lacking exon 9. S, Signal peptide; N, N-terminal cysteine-rich
region; LRR, leucine-rich motif region; H, hinge region; T and C, transmembrane
and C-terminal tail; U, unique C-terminal tail. B, Expression of LHR splice variants.
RNA extracted from cultured LGCs and a midluteal phase CL (mid CL) was used
as a template for RT-PCR using primers specific for each splice variant. All splice
variants were expressed in LGCs and mid CL and primers produced a single band
suitable for real-time quantitative PCR. C, Expression of individual LHR splice
variants in staged human corpora lutea using real-time quantitative PCR. LHRa
expression was significantly reduced in late luteal CLs compared with the
midluteal phase (P  0.01, Tukey). A similar nonsignificant trend was seen for
LHRb expression in these samples. LHRc expression was also significantly lower in
the late compared with the midluteal phase (P  0.05, Tukey). In contrast, a
significant increase in LHRd expression was observed in the late luteal CLs from
the early and midluteal phases (P  0.01 and P  0.05, respectively, Tukey). The
proportion of LHR variants during each stage of the luteal phase also changed
significantly (P  0.001, two-way ANOVA). In the midluteal phase, there was a
higher proportion of LHRa compared with LHRb and LHRc (P  0.05 and P 
0.001, respectively, Bonferroni). In the late-luteal phase, there was a higher
proportion of LHRd compared with the other LHR variants (P  0.001,
Bonferroni). Values are the mean  SEM. Different consecutive letters represent
statistical differences.
2874 Dickinson et al. Regulation of LH Receptor Splice Variants Endocrinology, June 2009, 150(6):2873–2881
 at Univ of St Andrews - Library Periodicals Dept on May 21, 2009 endo.endojournals.orgDownloaded from 
Corp., Gillingham, UK; 50 mg/liter); recombinant LH (Serono Labora-
tories; 10ng/ml) and50mg/literLDL; and recombinant humanactivin-A
(R&D Systems, Inc., Abingdon, UK; 25 ng/ml) or cortisol (Sigma-Al-
drich; 100 nM) for 24 h. Previous studies had determined that these doses
of activinA and cortisol had amaximal effect onLGCs (28, 29). For each
treatment controls containedanequivalent volumeof the carrier solution
and were conducted in parallel.
Tomimic the luteal phase, LGCs were plated as described above and
maintained for 12 d (25). Cells were stimulated with 1 ng/ml hCG and
50 mg/liter LDL from d 2 of culture, and this treatment was repeated
every second day until d 7. The remaining cells were given either 50
mg/liter LDL or 100 ng/ml hCG and 50 mg/liter LDL for an additional
6 d. Cells were collected at d 3 and 7 along with d 13 in the absence or
presence of hCG. Media were collected at the above time points and
measured for progesterone levels using an in-house RIA (25).
COS-7 cells were routinely maintained in DMEM (Life Technolo-
gies) supplemented with 10% fetal calf serum, penicillin/streptomycin,
and 2 mM glutamine (complete DMEM).
Expression analysis
RNA was extracted from cells and tissue using the RNeasy Mini kit
(QIAGEN Ltd., Crawley, UK) and treated with deoxyribonuclease I
(QIAGEN). RNA was used as a template for cDNA synthesis using
Taqman reverse transcriptase reagents (Applied Biosystems, War-
rington, UK). Primers specific for theLHR variants were designed based
on previous studies (17). PCR was performed on an Eppendorf Master-
cycler gradient authorized thermocycler (PerkinElmer, Inc., Waltham,
MA) usingGoTaq FlexiDNApolymerase (Promega Ltd., Southampton,
UK). The PCR thermocycle consisted of an initial denaturation of 5 min
at 95 C followed by 35 cycles of 95 C for 30 sec, annealing temperature
for 30 sec, 72 C for 30 sec, and a final extension of 10 min at 72 C. PCR
productswere purified usingQIAquick gel extraction kit (QIAGEN) and
verified by sequencing. Primers specific for the LHR variants were de-
signed based on previous studies (17) (see Table 1).
Real-time quantitative PCR
A standard curve was generated with serial dilutions of human CL
cDNA. Real-time PCR amplification was then performed in duplicate
10-l reactions using Platinum SYBR Green quantitative PCR Super-
MIX-UDG (Invitrogen) and the ABI 7900HT fast real-time PCR system
instrument (Applied Biosystems) (26). Each sample was normalized on
the basis of its glucose-6-phosphate dehydrogenase content by dividing
the amount of target gene by the amount of housekeeping gene.
Generation of plasmid constructs
LHRd was amplified by PCR from human CL cDNA using the Ex-
pand Long Template PCR system (RocheDiagnostics Ltd., Burgess Hill,
UK) and cloned into the pGEM-T Easy vector (Promega). The pSG5-
human wild-type LHRa construct was a gift from T. Hamalainen (Uni-
versity of Turku, Turku, Finland). These fragments were subcloned into
the KpnI and ApaI sites of the pDsRed-Monomer-C1 (CLONTECH
Laboratories Inc., Saint-Germain-en-Laye, France) and pEGFP-C1
(CLONTECH) vectors. They were also subcloned into the KpnI and
EcoRI sites of the pCDNA3.1/mycHisA vector (Invitrogen). All these
constructs were verified by sequencing.
cAMP assay
COS-7 cells were transiently transfected with 15 g of myc/His-
LHRa, myc/His-LHRd, myc/His-LHRa, and the pCDNA3.1mycHisA
empty vector or both myc/His-LHRa and myc/His-LHRd by electropo-
rationusing aBio-Radgenepulser (Bio-RadLaboratories,Hercules,CA)
(1.25106 transfected cells/well) (30).After 48h, completeDMEMwas
removed and cells were maintained in serum-free DMEM for 24 h.
Cells were incubated with serum-free DMEM containing 222 g/ml
isobutyl-1-methylxanthine (IBMX; Sigma-Aldrich), a phosphodiester-
ase inhibitor, for 30 min, allowing the accumulation of intracellular
cAMP. Next the cells were stimulated with recombinant LH (6.25 IU/
ml-6.25105 IU/ml) and IBMXin serum-freeDMEM.Each treatment
was carried out in duplicate. After 30 min, media were aspirated and
cAMP concentrations in pooled cell lysates were quantified using a com-
petitive enzyme immunoassay kit (R&D Systems). OD was measured
using a Multiskan EX microplate photometer (Thermo Fisher Scientific
Inc., Basingstoke, UK) at 450 nm.A standard curvewas generated and
sample concentrations were calculated using AssayZap computer
software (Biosoft, Cambridge, UK).
Confocal laser microscopy
COS-7 and LGCs were transiently transfected with pEGFP-C1-
LHRa, pEGFP-C1-LHRd, pEGFP-C1-LHRa, and pDsRed-Monomer-
C1-empty or pEGFP-C1-LHRa and pDsRed-Monomer-C1-LHRd.
COS-7 cells were transfected by electroporation as described above,
seeded in poly-D-lysine-coated glass-bottom culture dishes (MalTek,
Ashland, MA) (1.9  106 cells) and grown in complete DMEM. LGCs
were isolated from follicular fluid as described above, transferred to
culture dishes (4  105 cells/well), and cultured in DMEM/F12 Ham
supplemented with 10% fetal bovine serum 37 C and 5%CO2 for 24 h.
Cells were then transfected with 1 g of the indicated constructs using
FuGENE6 (Roche).After 24–48h,COS-7andLGCswerewashed twice
with PBS, fixed in 4% neutral buffered formaldehyde for 20 min, and
stored in PBS. Images were captured using a LSM510 Axiovert 100M
confocal laser microscope (Carl Zeiss Ltd., Welwyn Garden City, UK).
Statistical analysis
Parametric statistics were used as the data for all experiments were
normally distributed. A paired t test was used when treatment and con-
trol samples were analyzed. A one-way ANOVA was conducted when
more than two groups were compared and the data were categorized in
one way. When group means were significantly different by one-way
TABLE 1. Primers used in the expression analysis of candidate genes
Gene Primer locations (exons) Primer sequence (5–3) MgCl2 (mM) Annealing temp (C) Product size (bp)
LHRa (F) 9 ATTTGTCAATCTCCTGGAGGC 1.5 55 191
(R) 11 CACTCAGTTCACTCTCAGCA
LHRb (F) 8 and 10 AGGGCCGAAAACCTTACAGAA 1.5 55 131
(R) 11 CACTCAGTTCACTCTCAGCA
LHRc (F) 9 ATTTGTCAATCTCCTGGAGGC 1.5 55 167
(R) 10 and 11 CCCCATGCAAAAAGTGTTTTG
LHRd (F) 8 and 10 AGGGCCGAAAACCTTACAGAA 1.5 54 107
(R) 10 and 11 CCCCATGCAAAAAGTGTTTTG
G6PDH (F) 1 CGGAAACGGTCGTACACTTC 1.5 57 153
(R) 2 CCGACTGATGGAAGGCATC
Shown are each of the genes investigated, the exons to which primers were specific, primer sequences, and specific conditions used to amplify each product. The same
primers were used for real-time quantitative PCR. F, Forward primer; R, reverse primer; G6PDH, glucose-6-phosphate dehydrogenase.
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ANOVA (P  0.05), pairwise comparisons were performed using
Tukey’s multiple comparison test. A two-way ANOVA, followed by a
Bonferroniposttest,wasusedwhen twoormoredata setswere compared
for different factors. All statistical tests are highlighted in the figure
legends.
Results
Expression of truncated LHRs increased with CL age
Expression of LHR transcript variants was examined across
the luteal phase in well characterized CL samples (Fig. 1, B and
C). Real-time quantitative PCR revealed that expression of
LHRa and LHRd changed across the luteal phase (P  0.01,
one-way ANOVA). LHRa expression was reduced by 7-fold in
late-luteal CLs compared with the midluteal (P 0.01). In con-
trast, a 2- to 5-fold increase inLHRd expressionwas observed in
the late-luteal CLs from the early and midluteal (P  0.01 and
P  0.05, respectively). LHRc expression also changed during
the luteal phase and showed a similar trend toLHRa (P 0.05).
A 4-fold decrease in LHRc expression was observed in the late-
luteal CL compared with the midluteal phase (P  0.05).
The proportion of LHR variants during each stage of the
luteal phase changed (P  0.001, two-way ANOVA). In the
midluteal phase, there was a higher proportion of LHRa com-
pared with LHRb and LHRc (P  0.05 and P  0.001, respec-
tively, Bonferroni). In the late-luteal phase, there was increased
expressionofLHRd comparedwith theotherLHRvariants (P
0.001, Bonferroni). Therefore, as the CL approaches luteolysis,
there is an increase in the production of transcripts encoding
truncated LHRs. Because LHRa and LHRd showed the most
significant changes over the luteal phase, these variants were
investigated further.
Chronic manipulation of hCG increases LHRa and
decreases LHRd in cultured luteinized granulosa cells
The CL contains many different cell types that may change in
proportion across the luteal phase. To investigate the effects of
time and hCG on LHR transcript variants, primary cultures of
LGCwere studied using an in vitromodel designed to mimic the
stages of the luteal phase (Fig. 2). After 13 d in the presence of
increased hCG, progesterone concentrations were higher
(1131 44.27 ng/ml) than at d 3 or 7 of culture (P 0.001 and
P 0.01). Conversely, progesterone concentrationwas lower at
d 13 in the absence of hCG (119 10.12 ng/ml) compared with
d 7 and 13 with the gonadotropin (P  0.001). Using real-time
quantitative PCR, LHRa and LHRd expression changed under
these conditions (P 0.01 and P 0.05). Expression of LHRa
was 9-fold lower when gonadotropin treatment was withdrawn
(P  0.05) but increased by 12-fold under the presence of hCG
(P  0.01). In contrast, LHRd expression was 4-fold higher
when hCG was withdrawn (P  0.05) and 3.5-fold reduced in
cultureswith gonadotropin treatment (P0.05), supporting the
findings seen in the dated CL samples and suggesting hormonal
regulation of LHR splicing.
Expression of LHRa and LHRd is acutely regulated by
activin-A and cortisol in primary cell cultures
To determine whether the expression of LHRa and LHRd
could be acutely regulated by hCG, its effect on primary cultures
of LGCs was examined (Fig. 3A). Treatment with hCG for 24 h
didnot affectLHRaandLHRd expression.Likewise, themRNA
levels of LHRa and LHRd remained unchanged after LH treat-
ment for 24 h (Fig. 3B). We also investigated whether cortisol
could acutelymodulate the expressionofLHRaandLHRd.Cor-
tisol treatment for 24 h diminished expression of LHRa by 1.4-
fold and inducedLHRd expression by 2-fold in LGCs (P 0.05)
(Fig. 3C). Additionally, we assessedwhether activin-A could dif-
ferentially regulate expressionofLHRa andLHRd in LGCs (Fig.
3D). The expression of both transcript variants was reduced by
3-fold in activin-A-treated cells (P  0.05).
LHRd modulates the signal transduction by LHRa
Because these findings imply an inverse correlation in LHRa
andLHRd expression during theCL life span, the function of the
proteins they encode was investigated. LHRd is missing the
transmembrane domains and C-terminal tail suggesting it is un-
able to activate downstream signaling pathways such as cAMP
production. To confirm this hypothesis, COS-7 cells were tran-
siently transfected with either myc/His-LHRa or myc/His-
LHRd. The dose-response curves for LHRa and LHRd were
different from each other (P 0.001, two-wayANOVA). Treat-
ment with LH caused a dose dependent increase in cAMP pro-
duction in cells expressing LHRa. In contrast, a complete ab-
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FIG. 2. LHRa and LHRd expression was regulated in prolonged cultures of LGCs
designed to mimic the luteal phase. Cells were given low-dose hCG stimulation
for 1 wk and RNA was extracted at d 3 and 7. At d 7 cells were then cultured for
a further 6 d in the complete absence (), or with a maximal dose (), of hCG
and RNA was extracted from these cells at d 13. A, Withdrawal of hCG led to
reduction in LHRa expression (P  0.05, Tukey); however, mRNA levels were
restored in cultures given high doses of the hormone (P  0.01, Tukey). B,
Conversely, LHRd expression was maximal when hCG was withdrawn (P  0.05,
Tukey) and reduced in cultures with treatment (P  0.05, Tukey). Values are the
mean  SEM of three independent experiments. The asterisks correspond to P
values (*, P  0.05; **, P  0.01).
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sence of signal transduction was seen in cells transfected with
LHRd (Fig. 4A).
To examinewhetherLHRdmayaffect the signaling ofLHRa,
cAMP production was measured in COS-7 cells transiently co-
transfected with myc/His-LHRa and either myc/His-LHRd or
the pCDNA3.1mycHisA empty vector. The cAMP response of
cells coexpressing LHRa and LHRd to recombinant LH was
different from cells transfected with LHRa and the empty
vector (P 0.001, two-way ANOVA). After stimulation with
recombinant LH, cells coexpressing LHRd and LHRa had
undetectable cAMP levels. Conversely, cells transiently trans-
fected with LHRa and the empty vector responded to LH in a
dose-dependent manner (Fig. 4B).
LHRd effects the localization of LHRa
The absence of transmembrane and C-terminal domains sug-
gested that LHRd would not be localized to the plasma mem-
brane. Immunofluorescence staining of COS-7 cells transiently
transfected with green fluorescent protein (GFP)-LHRd con-
firmed that the variantwas localized intracellularly.GFP-LHRa,
on theotherhand,was expressedat the cell surface inCOS-7 cells
(Fig. 5A). This finding was verified in LGCs exogenously ex-
pressing GFP-LHRa or GFP-LHRd constructs (Fig. 5B).
To investigate whether LHRd causes misrouting of LHRa,
COS-7 cells were transiently transfected with GFP-LHRa and
eitherRFP-LHRdor thepDsRed-Monomer-C1-emptyvector. In
COS-7 cells transfected with LHRa alone, LHRa was apparent
in theplasmamembrane andadiffuse perinuclear network.Con-
versely, in COS-7 cells coexpressing both isoforms, LHRa and
LHRd showed similar staining inside the cell (Fig. 5C). Com-
parable results were seen in LGCs cotransfected with GFP-
LHRa and either RFP-LHRd or the pDsRed-Monomer-C1-
empty vector (Fig. 5D).
Discussion
Previously we detected expression of the
full-length LHR and three other splice vari-
ants in human CL (17). We were unable,
however, to assess whether the relative ex-
pression of each transcript variant changed
across the luteal phase. In this study we de-
signed primers specific for each transcript
variant and used real-time quantitative PCR
to quantify the LHR transcripts. There was
significantly increased LHRd and reduced
LHRa expression in the late-luteal CL sam-
ples. An in vitro model, in which the luteal
phase was mimicked in LGCs, mirrored
these findings. Reduction of LHR signaling
using hCG withdrawal increased LHRd ex-
pression, whereas increasing hCG concen-
trations maintained full-length LHRa
expression.
In humans it is not known how luteolysis
is regulated at the molecular level. It seems
that the LHR expression in human corpora
lutea is lower during luteolysis (18). How-
ever, in the late-luteal phase, when proges-
terone secretion is falling LHR expression is maintained (3).
Because LH and the steroidogenic machinery (4) are retained,
changes in functional LHRare implicated in the demise of theCL
(31). Previous experiments (3, 21) on human lutealLHR expres-
sion used Northern blotting, and it was not clear whether the
probe used was detecting all or just some of the LHR variants.
Although totalLHR expressionmight bemaintained in the func-
tional human CL, it appears, from our data, that expression of
the full-length receptor is reduced in the late luteal phase,
whereas there is increased expressionof truncatedLHRvariants.
Minegishi et al. (21) also recently used real-time quantitative
PCR to compare expression of LHR transcripts with and with-
out exon 9 across the luteal phase. There was increased expres-
sion of LHR transcripts without exon 9 compared with variants
with exon 9 as the luteal phase progressed, supporting our data.
Because their primers theoretically detected both LHRb and
LHRd, their results are difficult to fully relate to our findings
with regard to LHRb expression in which we did not see an
increase in the late luteal phase. However, expression of trun-
catedLHR splice variants seems to increase at the expense of the
full-length receptor as the CL matures.
Our studies measured mRNA expression, so it is not known
whether these LHR variants were translated into proteins in the
CL orwhether therewas posttranslationalmodification over the
luteal phase. Despite numerous attempts, we have not been able
to identify a sensitive and specific antibody to the human LHR
to test this fully by immunoblotting.However, in the sheepovary
a LHR splice variant with partial deletion of exon 11, encoding
a protein with no transmembrane or intracellular domains, was
translated in vivo (32). This is supported by the observation that
our LHRd constructs were translated in LGC and COS-7 cells.
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FIG. 3. Cortisol- and activin-A-regulated LHRa and LHRd expression in LGCs. The mean expression of
control-treated cells was normalized to 1. Values are the mean  SEM of three independent experiments.
A, Culturing LGCs with hCG (100 ng/ml) had no significant effect on LHRa and LHRd expression. B, The
addition of LH (10 ng/ml) to cultures of LGCs for 24 h had a nonsignificant effect on LHRa and LHRd
expression. C, Cortisol-treated LGCs had reduced LHRa and increased LHRd expression (P  0.05, paired t
test). D, Activin-A treatment caused a reduction in expression of both LHRa and LHRd (P  0.05, paired t
test). The asterisks correspond to P values (*, P  0.05).
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In prolonged cultures of LGCs treated with hCG, with in-
creased progesterone concentrations, imitating the effects of
early pregnancy, there was significantly increased expression of
LHRa anddiminishedmRNA levels ofLHRd. This suggests that
LHR transcripts are regulated in luteal cells and could be influ-
enced by the cellular environment. Regulation by hCG could be
influencing LHR splicing, or it may be controlling gene tran-
scription and/or mRNA degradation. Recent reports in the rat
ovary have suggested that hCG treatment induces the expressionof
mevalonate kinase, which can then bind to LHR mRNA and ac-
celerate its degradation (33).Whethermevalonatekinasehas a sim-
ilar role in humans and has different affinities to all the LHR tran-
scripts requires investigation. It isdifficult toknowhowhCGaffects
the expression pattern ofLHR variants.We believe that progester-
one could be mediating the effect because we have shown that
blockage of progesterone is toxic to these cells (25, 29). Estradiol
can enhance FSH-induced LHR mRNA in cultured rat gran-
ulosa cells (34). We did not include a substrate for estradiol in
our medium, so we cannot exclude the possibility that estro-
gen could be involved in the regulation of LHR transcripts.
It is possible that one of the roles of hCG during maternal
recognition of pregnancy is to maintain more full-length LHRa
expression as well as global LHR expression (3). Ideally cAMP
and ligand binding experiments would have been performed on
the prolonged cultures of LGC when hCG was withdrawn to
investigate whether there was a decrease in cell surface LHRs
during the in vitro luteal phase. However, these cells are termi-
nally differentiated, do not divide, collected in small amounts,
and increasingly disappear from prolonged cultures (27). There-
fore,wewerenot able toobtain the largenumberof cells required
for such experiments. Whereas past studies have measured
cAMP production in LGCs, measurements were made after cul-
turing for 48 h, not 13 d (35). Furthermore, it would have been
interesting to extend the culture course to see the effect of hCG
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FIG. 4. LH stimulation of cAMP production by COS-7 cells expressing variants of
the LHR. COS-7 cells were transiently transfected with myc/His tagged LHRa,
myc/His tagged LHRd, myc/His tagged LHRa and the pCDNA3.1mycHisA empty
vector, or both myc/His tagged LHRa and myc/His tagged LHRd. Cells were then
stimulated with serial dilutions of recombinant LH and 222 g/ml IBMX for 30
min. The cAMP parameter assay (Roche) was conducted according to the
manufacturers’ instructions. Values are the mean  SD of three independent
experiments. A, COS-7 cells expressing LHRa responded to LH, whereas an
absence of signal transduction was seen in cells transfected with LHRd. The dose-
response curves for LHRa and LHRd were significantly different (P  0.001, two-
way ANOVA). B, The presence of LHRd ablated the LHRa cAMP response to LH in
transiently transfected COS-7 cells. The cAMP accumulation in the COS-7 cells
transfected with LHRa and LHRd was at undetectable levels. The dose response
curves for cells transfected with LHRa and either LHRd or an empty vector were
significantly different (P  0.001, two-way ANOVA). The asterisks denote
statistically significant differences between the two curves by Bonferroni and
correspond to P values (**, P  0.01; or ***, P  0.001).
FIG. 5. Localization of LHR variants in COS-7 cells and LGC. A, LHRa and LHRd
were subcloned into the pEGFP-C1 vector (CLONTECH) and then transiently
transfected into COS-7 cells. Whereas LHRa was localized to plasma membrane,
LHRd showed a cytoplasmic distribution. B, The findings were confirmed in LGCs
transiently transfected with either GFP-LHRa or GFP-LHRd. The cell nuclei were
stained with 4,6-diamidino-2-phenylindole (DAPI). C, LHRd was also subcloned
into the pDsRed-Monomer-C1 vector (CLONTECH). COS-7 cells were transiently
transfected with GFP-tagged LHRa and either red fluorescent protein (RFP)-
tagged LHRd or the pDsRed-Monomer-C1 empty vector. When the RFP empty
vector was present, LHRa was localized mainly to the plasma membrane and
perinuclear network. In cells expressing LHRa and LHRd, both proteins colocalized
inside the cell. D, A similar result was observed in LGCs exogenously expressing
GFP-LHRa and either RFP-LHRd (bottom panel) or pDsRed-Monomer-C1-empty
(top panel). The cell nuclei were stained with DAPI. Results are representative of
three independent experiments.
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on the expression of LHRa and LHRd in a long-term culture
system. However, primary LGCs have a 14-d life span and only
survive under the influence of maximal hCG doses. Therefore,
we would be unable to conduct controls for this experiment.
Although short-term exposure to LH or hCG did not signif-
icantly alter LHR splicing, other local factors could influence
LHR expression. We have shown that activin-A has luteolytic
properties in human luteal cells and therefore could be a possible
regulator of LHR expression (28). However activin-A reduced
expressionof all fourLHRsplice variants to a similar level. In the
rat activin-A facilitates granulosa cell function (36) and enhances
p450 aromatase activity, a hallmark of gonadotropin action, in
rat (37) and bovine granulosa cells (38) as well as immature and
preovulatory marmoset follicles (39). Conversely, activin-A
seems to have an opposing role in human lutein cells in which it
hindered p450 aromatase activity and expression along with
estradiol production (40, 41). Additionally, activin decreased
basal and hCG-induced progesterone production in human
granulosa lutein cells (42) and culturedmacaque luteal cells (43).
Overall, it seems that activin-A can suppress LHR expression,
and this may have a role during luteolysis. However, activin-A is
not responsible for the differential expression of LHR transcript
variants.
The steroid cortisol did appear to influence LHR expression
in LGC cultures. This glucocorticoid significantly diminished
LHRa and induced LHRd expression in cultured LGCs.
Whereas this has not been reported in the human ovary before,
the full-length LHR mRNA was reduced by cortisol in cultures
of porcine granulosa cells (44). Furthermore, the number of
LHRs in cultured bovine granulosa cells was significantly re-
duced by cortisol in a dose-dependent manner (45). Previous
findings have also implicated other glucocorticoids in inhibition
of testicular LHR content and steroidogenesis (46) along with
LH-induced steroidogenic acute regulatory protein levels and
progesterone production in cultured rat preovulatory follicles
(47). The mechanism by which glucocorticoids exert this effect
may involve influencing the synthesis of membrane phospholip-
ids (48) or hampering intracellular cAMP (45). However, we
have shown that local cortisol generation is associatedwith hCG
action and luteal rescue rather than luteolysis (26, 29). Cortisol
also seems to negatively regulate putative luteolytic factors (26).
It is therefore not clearwhat the functional role of cortisol iswith
regards to LH action, and further research is needed.
Our in vivo and in vitro results implied that as the CL ages,
there is increased production of the most truncated form of the
receptor. This isoform, LHRd, lacks the transmembrane and
C-terminal domains, suggesting this truncated receptorwouldbe
unable to activate second-messenger signaling. Due to the limi-
tations of working with terminally differentiated primary cells,
we used COS-7 cells to investigate the functional properties of
LHRd. COS-7 cells have been used successfully in the past as a
model for examining the biological significance of human nat-
urally occurring LHR mutants (7) and splice variants (18).
COS-7 cells expressing LHRd and stimulated with LH did not
produce cAMP, confirming this prediction. Furthermore,COS-7
cells expressing LHRa and LHRd did not generate cAMP in
response to LH. This indicated that LHRd may have a negative
effect on LHRa cell surface expression. Similar results have been
seen in experiments with LHRb (19). This implies that the N-
terminal and LRR1-7 regions of the extracellular domain could
be involved in the phenomenon rather than the hinge region,
transmembrane segments, loops, andC-terminal tail. Truncated
forms of other GPCRs may also inhibit the signaling of their
corresponding wild-type receptor (49, 50).
The rodent LHR can undergo desensitization from its ligand
or uncoupling from second-messenger systems (51). During hu-
man luteolysis there is a decline in LH-induced progesterone
synthesis despite continued LH secretion (38) and expression of
other members of the steroidogenic pathway such as steroido-
genic acute regulatory protein, P450 side-chain cleavage, and
3-hydroxysteroid dehydrogenase (4). There also seems to be no
ligand-induced down-regulation of LHR because previous stud-
ies have shownmaintenance of mRNA levels and ligand binding
throughout the menstrual cycle (3). In these studies total LHR
mRNA and ligand binding were measured. This does not ac-
count for the possible negative effects truncated LHR isoforms
mayhaveon the full-length receptor’s activity.Our resultswould
imply that in humans a variant LHRcould inhibit the cell surface
expression of the full-length LHR, and this may have an impor-
tant contribution to luteolysis.
Immunofluorescence staining, in LGC and COS-7 cells, re-
vealed that LHRd is localized intracellularly. LHRb and a rat
LHR truncated splice variant, with partial deletion of exon 11,
reside mainly in the endoplasmic reticulum (ER) due to misfold-
ing (19, 23). Furthermore, the rat variant was found to localize
with the ER chaperones calnexin and calreticulin in a specialized
juxtanuclear subcompartment of the ER before being targeted
for the ERassociated degradation pathway (23). These ER chap-
erones have also been shown to associate with immature forms
of human LHR, FSHR, and TSH receptor along with misfolded
LHR mutants (52). In LGC and COS-7 cells transfected with
LHRd, LHRa seemed to be localized within the cell. However,
we did not quantify the result, so we cannot exclude the possi-
bility that there is still some cell surface expression of LHRa.
Furthermore, the ratLHRsplice variant, lacking transmembrane
and C-terminal domains, colocalized with immature LHRs and
redistributed them to the juxtanuclearER subcompartment (23).
Splice variants of other GPCRs appear to have a comparable
effect and function as dominant negatives tomediate misrouting
of their correspondingwild-type receptors to the ER (19, 23, 50,
53, 54). Moreover, coexpression of the rat LHR splice variant,
missing transmembrane, and C-terminal domains, with the full-
length LHR, resulted in a reduced number of LHRs at the cell
surface (23).
Research in the bovine indicated that detergent solubilization
of cells transfected with truncated LHR splice variants, with a
structure akin to LHRd, have the same hCG binding affinity as
the full-length LHR. No binding activity was observed in intact
cells expressing these forms though (16). In addition, past find-
ings have implied that LHRb, missing exon 9, is unable to bind
hCG at the cell surface (19). Because LHRd is missing exon 9, as
well as part of exon 11, it is likely that this variant is incapable
of interacting with either ligand at the cell surface, although we
did not test this hypothesis directly. Previous research demon-
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strated 125I-LH binding activity in thin tissue sections and tissue
homogenates at all stages of the luteal phase andduringmaternal
recognition of pregnancy (3, 55). In both these studies, however,
it is difficult to conclude whether there were changes in LHR
numbers at the cell surface across the luteal phase.
It is possible that the truncated variant functions as a chap-
erone or degradation assistant, and this warrants further eluci-
dation.Misrouting of the full-length receptor could be a result of
dimerization with the variant. Past findings have shown that
LHRb,missing exon 9, interactswith and reduces the expression
of the full-length LHR as well as the FSHR (19, 22). In these
studies the receptor complexes were transferred to the lysosome
in which they were eventually degraded. Additionally, previous
research indicated that the FSHR extracellular domain is able to
dimerize in the absence of theC-terminal half of the protein (56).
Further studies are required to investigate whether LHRa and
LHRd can heterodimerize. However our preliminary studies
(data not shown), and research of Apaja et al. (23) using the rat
LHR variant missing the transmembrane and C-terminal do-
mains, failed to detect dimerization of the truncated LHR with
the full-length receptorbycoimmunoprecipitation.This suggests
that a stable interaction between this particular LHRvariant and
LHRa is unlikely to take place. It is possible that cotransfection
of LHRd with LHRa was having an indirect effect on the ex-
pression of the full-length receptor, possibly through exhausting
transcriptional and/or translational machinery. Data on LHRb,
however, indicated that whereas it reduces LHR and FSHR cell
surface expression, it has no effect on the TSH receptor (19, 21,
22). We are currently dissecting the underlying mechanism by
which LHRd reduces LHRa cell surface expression.
In conclusion, in vivo, as the CL approaches luteolysis, there
is increased expression ofLHRd, the most truncated form of the
LHR. Furthermore, mimicking luteal rescue of pregnancy, by
treating LGC cultureswith hCG, increasedLHRa and decreased
LHRd expression.Whereas we have not confirmedwhether this
variant is translated into a protein in the human CL, in vitro
expression studies in LGC and COS-7 cells suggest LHRd re-
duces cell surface expression of LHRa. Overall, our findings
indicate that the expression of LHR transcript variants is regu-
lated in the human CL, and during luteolysis a truncated splice
variant negatively regulates the cell surface expression and ac-
tivity of the full-length LHR.
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